Corestem announced on the 26th that the results of the Phase 1 clinical study conducted for the purpose of confirming the safety of autologous bone marrow-derived mesenchymal stem cell treatment for patients with multiple system atrophy patients were published in an international academic journal.
Multiple system atrophy is a chronic degenerative disease that clinically shows Parkinson’s symptoms but is accompanied by abnormal symptoms of other nervous systems. To this day, the cause of the disease has not been identified, and about 3 to 5 years after the onset of symptoms, it becomes difficult to walk alone, and various complications can occur.
In addition, although many studies are being conducted to develop a therapeutic agent, a fundamental therapeutic agent has not been developed so far, and although Levodopa is used to alleviate Parkinson’s symptoms, the response to the drug is not high.
Among these, Corestem conducted phase 1 clinical trials with Professor Pil-Hyu Lee of the Department of Neurology, Yonsei University Severance Hospital, and a total of 9 patients diagnosed with multiple system atrophy within 5 years of onset using an open-label and single-dose method. The safety of the administration route was confirmed by dividing the group into three groups, and it was confirmed that the plasma levels of some pro-inflammatory cytokines decreased after administration of the drug.
Regarding this thesis, the researcher of Corestem said, “Through this clinical trial, it is expected that it will scientifically prove that the administration of therapeutic agents through arteries is safe and that it will lead to a new strategy in developing therapeutic agents for multiple system atrophy.” said
In addition, based on the results obtained through this clinical trial, the company said that it will do its best to produce good results in the future by making more efforts to develop a treatment for intractable nervous system diseases for the disease and similar diseases.
